{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2(4)"],"submitter":["Aribi A"],"pubmed_abstract":["IO-202 is a humanized immunoglobulin G1 monoclonal antibody with high affinity and specificity for leukocyte immunoglobulin-like receptor B4 (LILRB4; ILT3), which is predominantly expressed in monocytes and monocytic blasts. IO-202 induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis in vitro and in patients with leukemia. Herein, we present the phase 1a dose escalation data of IO-202 as monotherapy and in combination with azacitidine (AZA) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and R/R chronic myelomonocytic leukemia (CMML), and the phase 1b dose expansion data of IO-202 combined with AZA for the treatment of hypomethylating agent (HMA)-naïve CMML. IO-202 was well tolerated as monotherapy and in combination with AZA"],"journal":["Blood neoplasia"],"pagination":["100126"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12409809"],"repository":["biostudies-literature"],"pubmed_title":["A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia."],"pmcid":["PMC12409809"],"pubmed_authors":["Liu H","Madanat YF","Xiang H","Klencke B","Mannis GN","Jonas BA","Roboz GJ","Garcia-Manero G","Liao XC","Blum W","Pollyea DA","Aribi A","Huang T","DiNardo CD","Carraway HE","Saultz JN","Schiller G","Jeyakumar D","Woodard P","Dunavin N"],"additional_accession":[]},"is_claimable":false,"name":"A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia.","description":"IO-202 is a humanized immunoglobulin G1 monoclonal antibody with high affinity and specificity for leukocyte immunoglobulin-like receptor B4 (LILRB4; ILT3), which is predominantly expressed in monocytes and monocytic blasts. IO-202 induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis in vitro and in patients with leukemia. Herein, we present the phase 1a dose escalation data of IO-202 as monotherapy and in combination with azacitidine (AZA) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and R/R chronic myelomonocytic leukemia (CMML), and the phase 1b dose expansion data of IO-202 combined with AZA for the treatment of hypomethylating agent (HMA)-naïve CMML. IO-202 was well tolerated as monotherapy and in combination with AZA","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-02T05:22:03.296Z","creation":"2026-04-14T03:13:47.119Z"},"accession":"S-EPMC12409809","cross_references":{"pubmed":["40919482"],"doi":["10.1016/j.bneo.2025.100126"]}}